Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2026 | ODYSSEY: real-world QOL outcomes on IO regimens in metastatic RCC

Michael Harrison • 26 Feb 2026
GU Cancers 2026
Genitourinary Cancer Kidney Cancer Antibodies
ODYSSEY

Michael Harrison, MD, Duke University School of Medicine, Durham, NC, discusses real-world quality of life (QOL) outcomes in patients with metastatic renal cell carcinoma (RCC) receiving immunotherapy-based combinations from the ODYSSEY observational study (NCT04319122). The analysis examined patient-reported outcomes across various treatment regimens during early follow-up. Results showed generally maintained quality of life scores with some variation between different combination therapies. This interview took place at the 2026 ASCO GU Cancers Symposium in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Michael Harrison

Using early QoL data to identify patients with high-risk RCC
0:55
Using early QoL data to identify patients with high-risk RCC
Michael Harrison • 26 Feb 2026
ODESSY: real world outcomes on active surveillance in mRCC
3:37
ODESSY: real world outcomes on active surveillance in mRCC
Michael Harrison • 31 May 2025
The role of active surveillance for patients with metastatic kidney cancer
1:24
The role of active surveillance for patients with metastatic kidney cancer
Michael Harrison • 31 May 2025

Related Videos

Current and emerging systemic strategies in biochemically relapsed prostate cancer
2:45
Current and emerging systemic strategies in biochemically relapsed prostate cancer
Ashwin Sachdeva • 16 May 2026
How has SABR improved radiotherapy practice in kidney cancer?
1:06
How has SABR improved radiotherapy practice in kidney cancer?
Shankar Siva • 16 May 2026
Which patients with kidney cancer may benefit from SABR treatment?
1:58
Which patients with kidney cancer may benefit from SABR treatment?
Shankar Siva • 16 May 2026
Management of brain metastasis in patients with poor-risk testicular cancer
1:03
Management of brain metastasis in patients with poor-risk testicular cancer
Darren Feldman • 30 May 2026
The content of VJOncology is intended for healthcare professionals